ArticleJournal of the American Academy of Dermatology2023
The blood proteomic signature of prurigo nodularis reveals distinct inflammatory and neuropathic endotypes: A cluster analysis.
Article in Journal of the American Academy of Dermatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 16 citations in OpenAlex.
- Comprehensive Transcriptomic Profiling of Nonatopic Prurigo Nodularis in Korean Patients Reveals Il-22-driven Epidermal Stress and Neuro-immuno-fibrotic Remodelling.Acta dermato-venereologica · 2026Article
- Article
- Association of the inflammatory marker suPAR with chronic pruritus of unknown origin - data from the SOMA.PRU study.Frontiers in immunology · 2026Article
- IgE-defined endotypes reveal distinct clinical profiles of prurigo nodularis compared with atopic dermatitis: a multicenter study in China.Frontiers in allergy · 2026Article
- Circulating IgE levels as a biomarker for treatment response to dupilumab among patients with prurigo nodularis.Clinical and experimental dermatology · 2025Article
- Prurigo nodularis: new insights into pathogenesis and novel therapeutics.The British journal of dermatology · 2024Review
- Comprehensive plasma cytokine and chemokine profiling in prurigo nodularis reveals endotypes in Type 2 inflammation.Scientific reports · 2024Article
- Data independent acquisition reveals in-depth serum proteome changes in uremic pruritus.Frontiers in physiology · 2024Article
- Chronic Prurigo Including Prurigo Nodularis: New Insights and Treatments.American journal of clinical dermatology · 2024Review
- Clinical utility of peripheral blood laboratory testing in the diagnostic workup of prurigo nodularis: A multicenter cohort study.JAAD international · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundPrurigo nodularis (PN) is an extremely pruritic, chronic inflammatory skin disease. Little is known about systemic inflammation in PN.
objectiveTo characterize plasma inflammatory biomarkers in patients with PN and investigate the presence of disease endotypes.
methodsIn this cross-sectional study, Olink proteomic analysis was performed on plasma samples from patients with PN (n = 29) and healthy controls (n = 18).
resultsPatients with PN had increased levels of 8 circulating biomarkers compared to controls, including tumor necrosis factor, C-X-C Motif Chemokine Ligand 9, interleukin-12B, and tumor necrosis factor receptor superfamily member 9 (P < .05). Two PN clusters were identified in cluster 1 (n = 13) and cluster 2 (n = 16). Cluster 2 had higher levels of 25 inflammatory markers than cluster 1. Cluster 1 had a greater percentage of patients with a history of myelopathy and spinal disc disease compared with cluster 2 (69% vs 25%, P = .03). Patients in cluster 2 were more likely to have a history of atopy (38% in cluster 2 vs 8% in cluster 1, P = .09). LIMITATIONS: Small sample size precludes robust subgroup analyses.
conclusionThis study provides evidence of neuroimmune-biased endotypes in PN and can aid clinicians in managing patients with PN that are nonresponsive to traditional therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.